Jade Biosciences, Inc. Common Stock earnings per share and revenue
On 13 de nov. de 2025, JBIO reported earnings of -0.48 USD per share (EPS) for Q3 25, beating the estimate of -0.68 USD, resulting in a 30.18% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +10.54% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analistas forecast an EPS of -0.52 USD, with revenue projected to reach -- USD, implying an aumentar of 8.33% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
What were Jade Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Jade Biosciences, Inc. Common Stock reported EPS of -$0.48, beating estimates by 30.18%, and revenue of $0.00, 0% as expectations.
How did the market react to Jade Biosciences, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 10.54%, changed from $9.68 before the earnings release to $10.70 the day after.
When is Jade Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for 23 de mar. de 2026.
What are the forecasts for Jade Biosciences, Inc. Common Stock's next earnings report?
Based on 9
analistas, Jade Biosciences, Inc. Common Stock is expected to report EPS of -$0.52 and revenue of -- for Q4 2025.